News

LIXTE Secures U.S. Patent for Innovative Cancer Treatments

LIXTE Secures U.S. Patent for Innovative Cancer Treatments

LIXTE’s New Patent Enhances Cancer Treatment Innovations

Overview of the Patent

LIXTE Biotechnology Holdings, Inc. (NASDAQ: LIXT and LIXTW) has recently garnered attention after receiving a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its U.S. Patent application numbered 16/467,721. This patent, titled "Oxabicycloheptanes for Modulation of Immune Response," specifically addresses the combination of its innovative LB-100 compound with a range of advanced cancer immunotherapies.

Insights from the CEO on the Patent Award

Bas van der Baan, the Chief Executive Officer of LIXTE, shared that this new patent significantly bolsters the company’s intellectual property portfolio. He highlighted that this accomplishment reflects LIXTE’s steadfast dedication to pioneering research aimed at delivering effective solutions for patients battling cancer.

Development of LB-100

LIXTE is actively developing LB-100, a first-in-class lead clinical PP2A inhibitor that aims to improve the effectiveness of cancer immunotherapy. Currently, the company is conducting clinical trials at prestigious institutions, including the Netherlands Cancer Institute (NKI) and The University of Texas MD Anderson Cancer Center in Houston.

Collaboration with Top Institutions

At NKI, LIXTE provides LB-100, while F. Hoffmann-La Roche Ltd. supplies atezolizumab (Tecentriq), a PD-L1 inhibitor, as part of a collaborative initiative known as the imCORE Network. This project aims to accelerate research in cancer immunotherapy through partnerships between academia and industry, specifically targeting patients with unresponsive metastatic colon cancer.

Additional Clinical Studies at MD Anderson

Moreover, another clinical trial at MD Anderson is exploring the effects of combining LB-100 with GSK’s dostarlimab-gxly, focusing on treatment options for ovarian clear cell carcinoma (OCCC).

Exclusive Licensing Agreement and Future Opportunities

The recent patent approval comes on the heels of LIXTE’s exclusive patent licensing agreement with the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI) that was established earlier this year. This agreement provides LIXTE with the opportunity to further investigate innovative combination therapies that could potentially transform cancer treatment approaches.

About LIXTE Biotechnology Holdings, Inc.

LIXTE is a clinical-stage pharmaceutical company focused on discovering new pathways in cancer drug development. The company is dedicated to creating and commercializing effective cancer therapies. Their lead clinical candidate, LB-100, has demonstrated promising tolerance and anti-cancer activity in patients, paving the way for enhancing conventional chemotherapies and immunotherapies.

LIXTE is at the forefront of a new area of cancer biology called activation lethality. The company’s extensive patent portfolio supports their innovative strategies, with ongoing clinical trials currently targeting colon, ovarian, and sarcoma cancers.

Contact Information

For more information, LIXTE welcomes inquiries through the following contacts:

Email: info@lixte.com
General Phone: (631) 830-7092
Investor Phone: (888) 289-5533

Alternatively, you can reach out to Investor Relations at PondelWilkinson Inc.:
Email: pwinvestor@pondel.com
Roger Pondel: (310) 279-5965
Laurie Berman: (310) 279-5962

Frequently Asked Questions

What is the significance of LIXTE's recent patent?

This patent enables LIXTE to safeguard its innovative method of combining LB-100 with new cancer immunotherapies, thereby enhancing their research initiatives.

What is LB-100?

LB-100 is LIXTE’s leading clinical compound designed to inhibit PP2A, serving as a potentiator in cancer immunotherapy.

How does LIXTE collaborate with research institutions?

LIXTE partners with top institutions like NKI and MD Anderson to conduct clinical trials that utilize their compounds in conjunction with existing therapies.

What areas do LIXTE's clinical trials focus on?

LIXTE's trials concentrate on various cancers, including colon cancer and ovarian clear cell carcinoma, evaluating the effects of LB-100 in combination with other immunotherapies.

Where can I find more information about LIXTE?

For additional details about LIXTE and their ongoing projects, you can visit their official website directly.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Melio’s AP Push Looks Useful, but Read the Fine Print

Updated Category News Views 73

Back-office drudgery rarely gets anyone’s pulse racing, yet it can quietly chew through a small business’s time and cash. That is why Melio’s latest recognition as Software Experts’ top pick for accounts payable automation deserves a look. The product pitch is straightforward: pull bills, approvals, payments and reconciliation into one workflow rather than leaving...

Continue Reading
Illumina's Virtual Cell Win Raises Bigger AI Stakes

Updated Category News Views 70

A blind prediction contest is a useful place to separate glossy AI talk from actual biology. Illumina's BioInsight AI Lab took first place in Arc Institute's 2026 Virtual Cell Challenge, outperforming roughly 1,500 competitors on predictions of how cells would react when genes were knocked down. That is not a quarterly revenue number, and nobody should pretend otherwise....

Continue Reading
SDG&E's 21-Year Reliability Run Has Real Investor Weight

Updated Category News Views 56

Seventy minutes without power in a year is the sort of number most people ignore until their refrigerator quits humming. For San Diego Gas & Electric customers, though, it is a meaningful operating result: roughly 70 minutes annually from unplanned outages, on average, over the past decade, alongside fewer than one sustained outage per customer each year. SDG&E has also...

Continue Reading
SOCi's MCP Push Makes Context the Product Moat Bigger

Updated Category News Views 111

Software agents without decent business context are just eager interns with access to the keyboard. SOCi’s November 19, 2026 announcement gets at that unglamorous truth: the company has made its Model Context Protocol server generally available and says its context layer now connects with more than 140 integrations. It is not a flashy new chatbot stunt. It is a bid to...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 22

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
&honey's U.S. Beauty Awards Sweep Puts Distribution in Focus

Updated Category News Views 165

Three glossy-magazine nods may sound fluffy, but shelf momentum is never entirely fluff. Japanese haircare brand &honey says its Deep Moist Shampoo, Treatment and Hair Oil each landed 2026 recognition from Marie Claire, ELLE and Allure. For a consumer brand trying to make an American habit out of a Japanese haircare ritual, that is the sort of validation worth...

Continue Reading
YPTC’s Florida Office Bets on Nonprofit Finance Needs

Updated Category News Views 0

A Local Flag Planted After Years of Work Florida nonprofits do not need another consultant waving a glossy slide deck around; they need clean books, grant compliance, and somebody who can tell them where the cash is going before the lights start blinking red. That is the practical opening YPTC is chasing with a Jacksonville-based Florida office, its sixteenth office...

Continue Reading
Compounded Peptides Demand Clearer FDA Status Answers

Updated Category News Views 170

Peptide talk has gotten muddled enough to make plain English feel revolutionary. The central point in the HelloNation article featuring wellness expert Andres Giraldo is straightforward: a compounded peptide is not FDA approved in the same product-specific manner as a commercially manufactured drug. That is not a small semantic wrinkle, and it should not be buried beneath...

Continue Reading
StoneX Selloff Puts Earnings Quality Under a Harsh Lens

Updated Category News Views 111

A revenue beat can turn downright useless when the profit line springs a leak. StoneX Group delivered operating revenue above expectations and record full-year results, then watched investors hammer the stock after fiscal fourth-quarter diluted earnings per share landed at $0.66. That was $0.15 below the roughly $0.81 consensus cited in the notice, and other estimates...

Continue Reading
A. O. Smith's Sustainability Scorecard Has Real Teeth

Updated Category News Views 130

Numbers finally showed up wearing work boots in A. O. Smith’s latest sustainability report. The company says it beat every one of its three environmental targets, and the gaps were not the sort of rounding-error victories corporate communications teams love to polish until they shine. For investors following NYSE:AOS, that deserves a look—not a standing ovation, but a...

Continue Reading

Top 5 Most Recently Viewed Articles

BingX Enhances Trading Experience with CScalp Integration

Updated Category News Views 197

BingX Introduces Enhanced Trading Features with CScalp BingX, a prominent name in the cryptocurrency exchange sphere, has recently announced its integration with CScalp, a powerful trading terminal designed for both cryptocurrency and futures traders. This collaboration aims to provide users with cutting-edge trading tools, significantly enhancing their overall trading...

Continue Reading
Moscow Stocks Decline: Insights into Market Performance

Updated Category News Views 106

Moscow Stocks Face a Decline In the latest trading sessions, Moscow stocks have shown a clear downturn, with certain sectors especially driving this trend. The shifting dynamics within these sectors have created a challenging environment for investors. Performance by Sector and Important Takeaways The Telecoms, Mining, and Power sectors have been particularly tough,...

Continue Reading
Innovative Collaboration between Precision for Medicine and PathAI

Updated Category News Views 389

Strategic Alliance for Advancing Clinical Trials In a groundbreaking announcement, Precision for Medicine and PathAI are collaborating to revolutionize clinical trials and biomarker discovery. This partnership is set to introduce the next generation of AI-powered pathology tools designed to enhance quality control in clinical research. Enhancing Clinical Research...

Continue Reading
Declining Brazil Orange Juice Exports: Key Insights & Trends

Updated Category News Views 279

Overview of Brazil's Orange Juice Export Decline Brazil's orange juice exports have faced a significant downturn, with a 19.7% decrease in the first half of the 2024/25 crop season compared to the same time last year, as reported by CitrusBR. This decline represents approximately 535,600 metric tons of juice exports during this period, according to industry data....

Continue Reading
Celebrating 25 Years of Innovation in Legal Marketing

Updated Category News Views 164

Celebrating Two and a Half Decades of Digital Marketing PaperStreet Web Design, a pioneer in legal marketing, proudly marks its 25th anniversary. Founded by attorney and visionary Peter Boyd in 2001, this agency began as a one-person endeavor and has evolved into a nationally recognized firm employing over 30 professionals. With a rich history of aiding more than 2,500...

Continue Reading